January 28, 2015 4:33 AM ET


Company Overview of Cardio3 BioSciences SA

Company Overview

Cardio3 BioSciences SA, a biopharmaceutical company, discovers, develops, and commercializes regenerative and protective therapies for cardiovascular diseases in Belgium. It provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. The company’s products include C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy; and C3BS-GQR-1, a protein-based product candidate for protecting heart tissue from acute injury and promoting activation of resident cardiac stem cells in an acute myocardial infarction setting. Its preclinical stage products comprise C3BS-GQR-4, a protein based produc...

Rue Edouard Belin 12

Mont-Saint-Guibert,  1435


Founded in 2004

51 Employees


32 1 039 41 00


32 1 039 41 41

Key Executives for Cardio3 BioSciences SA

Chief Executive Officer and Executive Director
Age: 56
Total Annual Compensation: $315.0K
Compensation as of Fiscal Year 2013.

Cardio3 BioSciences SA Key Developments

Cardio3 BioSciences Appoints Vincent Brichard as Vice President Immuno-Oncology

Cardio3 BioSciences announced the appointment of Dr. Vincent Brichard as Vice President immuno-oncology. In this role, Dr. Brichard will lead the newly acquired immuno-oncology technology platform of Cardio3 BioSciences. Vincent Brichard is a physician by training, specialized in oncology, and holds a PhD in tumor immunology. He started his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels.

Cardio3 BioSciences Announces the Enrolment of the 240th Patient for its Chart-1 Phase III Clinical Trial for the Treatment of Heart Failure

Cardio3 BioSciences announced the enrolment of the 240th patient in its CHART-1 European trial for C-Cure®, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure. With recruitment that started in mid-2013, Cardio3 BioSciences has enrolled 240 patients in less than 18 months, ahead of schedule. As usual in clinical trials targeting severe indications, the company will continue to recruit additional patients in anticipation of patient dropouts. The CHART-1 trial is currently ongoing in 12 countries in Europe and Israel. The CHART-1 (Congestive Heart failure Cardiopoietic Regenerative Therapy) trial represents the world's first phase III trial for a pre-programmed cellular therapy for the treatment of heart failure.

Cardio3 BioSciences SA Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015

Cardio3 BioSciences SA Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015. Venue: Lyon’s Convention Center, Lyon, France. Presentation Date(s): Jan-08-2015. Jan-09-2015.

Similar Private Companies By Industry

Company Name Region
Artelis, S.A. Europe
PharmaDM Europe
Janssen Diagnostics BVBA Europe
R.E.D. Laboratories N.V./S.A. Europe
Probiox SA Europe

Recent Private Companies Transactions

January 6, 2015
Celdara Medical, LLC, Immuno-Oncology
November 5, 2014
CorQuest Medical Inc.
Private Placement
June 16, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cardio3 BioSciences SA, please visit www.c3bs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.